Lexeo Therapeutics, Inc. LXEO
3.31
(0.08)
(2.36%)
as of 25 Sep
- Market cap
- $278.3M
- P/E
- 0.0×
Follow LXEO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
13.49 | 13.61 | 10.81 | 7.11 | |
Current Ratio |
13.89 | 14.16 | 11.21 | 7.40 | |
Net Debt/EBITDA |
7.58 | 8.65 | 7.88 | 5.68 | |
Debt/Assets |
0.04% | 0.08% | 0.12% | 0.32% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 1.05 | 0.96 | 1.46 | |
Capex/Depreciation |
(0.07) | (1.13) | 0.00 | (2.17) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.26) | (0.37) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.26) | (0.37) | (0.49) | |
Cash per Share |
2.47 | 2.38 | 3.39 | 2.01 | |
Shareholders Equity per Share |
2.75 | 2.85 | 4.60 | 1.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.75 | 2.85 | 4.60 | 1.98 | |
Free Cash Flow |
(17.60) | (21.18) | (20.08) | (29.84) | |
Working Capital |
202.22 | 186.67 | 171.58 | 110.52 | |
Capital Expenditures |
(0.01) | (0.03) | 0.00 | (0.29) | |
Net Current Asset Value |
198.07 | 182.00 | 166.37 | 104.78 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
12.10 | 7.66 | 5.64 | 6.55 | |
Average Assets |
215.48 | 188.02 | 207.82 | 158.85 | |
Average Common Equity |
186.64 | 159.81 | 181.76 | 130.08 |
Columns are period end dates